3-Dimensional Pharmaceuticals Inc., of Exton, Pa., appointed to its scientific advisory board Ralph Hirschmann, a professor of bioorganic chemistry at the University of Pennsylvania.
AeroGen Inc., of Sunnyvale, Calif., appointed Carol Gamble vice president and general counsel.
Albany Molecular Research Inc., of Albany, N.Y., promoted Harold Meckler to vice president, science and technology; Bruce Molino to director, medicinal chemistry; Allen Salerno to assistant director, analytical services; and Peter Gruzzo to section head, medicinal chemistry.
Argonaut Technologies Inc., of San Carlos, Calif., named John Supan vice president of finance and chief financial officer. The company also elected to its board of directors Brian Metcalf, senior vice president and chief scientific officer at Kosan Biosciences.
Athersys Inc., of Cleveland, appointed Jeffrey Steinhilber chief financial officer.
BioChem Pharma Inc., of Laval, Quebec, promoted Ronald Ellis to senior vice president, vaccine research and development.
Celera Genomics, of Rockville, Md., named Jason Molle senior vice president of sales and marketing, and Peter Chambre chief operating officer.
Cell Robotics Inc., of Albuquerque, N.M., named Paul Johnson chief financial officer, Irene Ho international sales coordinator, Stephen Aiken laser engineer, and Elizabeth Reves sales manager, S.E. region.
Centaur Pharmaceuticals Inc., of Sunnyvale, Calif., named to its board of directors Richard Dunning, chairman and CEO of Nexell Therapeutics.
Coley Pharmaceutical Group, of Wellesley, Mass., named Robert Forrester senior vice president of finance and development, Yves Fouron vice president of corporate development, and Barbara Deptula vice president of commercial development.
COR Therapeutics Inc., of South San Francisco, promoted Peter Roddy to senior vice president, finance, and chief financial officer.
Eos Biotechnology Inc., of South San Francisco, named to its board of directors Nicholas Pritzker, chairman and CEO of Hyatt Development Corp. and Hyatt Equities LLC.
Genetronics Biomedical Ltd., of San Diego, appointed to its board of directors Grant Denison, co-founder, chairman and CEO of BioMarin Pharmaceutical Inc.
Glyko BioMedical Ltd., of Toronto, named to its board of directors Joerg Gruber, Hannes Glaus, John Klock, John Kolada, Urs Specker and Jeffrey Trossman.
Immunex Corp., of Seattle, named Barry Pea senior vice president, general counsel and secretary.
Interleukin Genetics Inc., of San Antonio, Texas, elected to its board of directors John Garofalo, a diplomat of the American Board of Obstetrics and Gynecology.
International Isotopes Inc., of Denton, Texas, named Paul Landers chief financial officer.
Iomed Inc., of Salt Lake City, appointed Steven Hamilton executive vice president in charge of the ophthalmic program, and Tim Miller executive vice president responsible for its local inflammation initiatives.
NeoTherapeutics Inc., of Irvine, Calif., named Mark Foreman senior director of research.
NPS Pharmaceuticals Inc., of Salt Lake City, appointed to its board of directors Tamar Howson, most recently senior vice president and director of worldwide business development at SmithKline Beecham plc.
Organogenesis Inc., of Canton, Mass., named Paul DiCicco vice president of operations.
Oxigene Inc., of Boston, named David Chaplin chief operating officer and head of research and development.
Procrea BioSciences Inc., of Montreal, named to its scientific advisory board Alan Wolffe, senior vice president and chief scientific officer at Sangamo BioSciences Inc.
Qiagen N.V., of Venlo, the Netherlands, named to its board of supervisory directors Heinrich Hornef, chairman of the supervisory board of Merck KgaA, and Manfred Karobath, a member of the Swiss Science and Technology Group.